Compare Kyndryl Holdings Inc (KD) vs TG Therapeutics Inc (TGTX) Price & Performance

Kyndryl (KD) trades at $13.025, down 4.44% on the day, with a neutral technical signal. The company reported a net loss in Q1 2027, missing revenue estimates, but maintains a strong cash flow position with $942M from operations in 2025. Recent news highlights strategic acquisitions and AI service expansions, while an ongoing legal investigation introduces uncertainty. The stock's valuation shows a high P/E of 36.11 but attractive EV/EBITDA of 4.04, with analyst consensus leaning hold.

The outlook is mixed: positive cash flow and strategic moves in AI modernization offer growth potential, but recent earnings misses and legal scrutiny pose risks. Investors should weigh the company's turnaround progress against execution challenges and market sentiment.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.